Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives

Tvardi Therapeutics, Inc.

Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.
Workforce reduction of approximately 70%, substantially complete by June 30, 2024.
Expects approximately $2.6M in total charges for termination benefits, recognized in Q2 and Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.